Dr. Stella Vnook explains how US pricing regulations, such as MFN and the IRA, are forcing pharma companies to adjust ...

Ireland has evolved into one of the world’s most critical locations for the global Pharmaceutical Industry. Today, with more ...

In today's Pharmaceutical Executive Daily, Eli Lilly announces a definitive agreement to acquire Ajax Therapeutics for up to ...

In January 2026, FDA issued draft guidance that expanded the potential use of real-world evidence (RWE) during the clinical ...

Total consideration reaches up to $2.3 billion via upfront payment plus milestones tied to predefined clinical and regulatory ...

FDA label expansion adds relapse-prevention in adult schizophrenia, addressing a major driver of hospitalization, functional ...

Increasingly complex cell therapy modalities, including multi-edit knock-in/knockout designs, are accelerating adoption of ...

While the goal is to reduce the cost burden on US patients, many in the industry are warning that there could be consequences ...

Gen2X enhances the RAIN RFID protocol with faster inventories, improved sensitivity/range, tighter read-zone confinement, and ...

Maher Masoud, CEO of MaxCyte, explains how the current environment is impacting the entrepreneurial spirit in the ...

Dr. Stella Vnook discusses how pricing transparency and VBC might have a more positive impact than MFN and other pricing regulations.

The FDA has granted Compass Pathways with a rolling review for a New Drug Application (NDA) for its investigational ...